The Best Way to Play the Biotech IPO Boom

Before you go, we thought you'd like these...
Before you go close icon

This episode of The Motley Fool's Market Checkup is dedicated to the massive increase in biotech IPOs, what's driving the recent spate of major mergers and acquisitions, whether the outperformance of the biotech sector is sustainable, and why potential biotech investors need to think big.

The amount of biotech stocks going public has increased from 11 in 2012 to already 29 this year -- and it's only August! Given the tremendous amount of enthusiasm for these offerings, a virtuous cycle has started to develop.

In this video, health-care analyst David Williamson discusses the winners of the biotech IPO boom, the potential downside to hopping on the bandwagon now, and a better way to invest in early stage drug makers.


Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.

The article The Best Way to Play the Biotech IPO Boom originally appeared on Fool.com.

Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners